# US 2020/0399312 A1 · Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2020/0399312 A1 - Document ID: US20200399312A1 - Status: Published application - Kind: A1 - Application number: 16/806,374 - Filed: 2020-03-02 - Published: 2020-12-24 - Earliest claimed: 2012-05-25 - Assignees: Agenus Inc.; The Board of Regents of the University of Oklahoma - Applicants: Agenus Inc.; The Board of Regents of the University of Oklahoma - Inventors: Donald F. HUNT; Andrew NORRIS; Ann Michelle ENGLISH; Jeffrey SHABANOWITZ; William H. HILDERBRAND; Oriana E. HAWKINS - Web page: https://patentgrep.com/patent/US20200399312A1 ## CPC - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 39/0011: {Cancer antigens} - A61P 35/00: Antineoplastic agents - A61P 37/04: Immunostimulants - C07K 7/06: having 5 to 11 amino acids - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C07K 16/18: against material from animals or humans - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/55: Fab or Fab' - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer. ## Claims ### Claim at position 1 1-20. (canceled) ### Claim 21 A composition comprising a peptide mimetic of a phosphopeptide, the phosphopeptide having a length of 10 to 30 amino acids and comprising a sequence selected from the group consisting of: SEQ ID NO: 132; SEQ ID NO: 132 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 71 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 72 wherein the serine at the eighth position is phosphorylated; SEQ ID NO: 73 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 75 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 76 wherein the serine at the eighth position is phosphorylated; SEQ ID NO: 78 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 79 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 80 wherein the threonine at the third position is phosphorylated; SEQ ID NO: 84 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 87 wherein the serine at the eighth position is phosphorylated; SEQ ID NO: 93 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 94 wherein the serine at the fifth position is phosphorylated; SEQ ID NO: 97 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 99 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 100 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 101 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 102 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 104 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 105 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 110 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 112 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 113 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 114 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 115 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 117 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 118 wherein the serine at the tenth position is phosphorylated; SEQ ID NO: 120 wherein the threonine at the fourth position is phosphorylated; SEQ ID NO: 126 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 127 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 135 wherein the serine at the sixth position is phosphorylated; SEQ ID NO: 140 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 143 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 145 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 146 wherein the tyrosine at the fifth position is phosphorylated; SEQ ID NO: 149 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 151 wherein the serine at the eighth position is phosphorylated; SEQ ID NO: 153 wherein the serine at the seventh position is phosphorylated; SEQ ID NO: 154 wherein the serine at the fifth position is phosphorylated; SEQ ID NO: 160 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 161 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 162 wherein the serine at the fourth position is phosphorylated and the serine at the eighth position is phosphorylated; SEQ ID NO: 163 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 166 wherein the serine at the seventh position is phosphorylated; SEQ ID NO: 167 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 168 wherein the serine at the fourth position is phosphorylated; SEQ ID NO: 169 wherein the serine at the fourth position is phosphorylated; and SEQ ID NO: 170 wherein the serine at the seventh position is phosphorylated. ### Claim 22 (depends on 21) The composition of claim 21, further comprising an adjuvant. ### Claim 23 (depends on 22) The composition of claim 22, wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, aluminum hydroxide, lysolecithin, pluronic polyols, dinitrophenol, bacille Calmette-Guerin (BCG), and Corynebacterium parvum, or combinations thereof. ### Claim 24 (depends on 21) The composition of claim 21, wherein said composition has the ability to stimulate a T cell mediated immune response to at least one of said peptide mimetics of a phosphopeptide. ### Claim 25 (depends on 21) The composition of claim 21, comprising a peptide mimetic of a phosphopeptide capable of binding to the HLA-B*0702 allele on the MHC class I molecule. ### Claim 26 (depends on 21) A method of inducing an immunogenic response comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 21. ### Claim 27 (depends on 21) A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 21. ### Claim 28 (depends on 21) A method of treating breast cancer comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 21. ### Claim 29 (depends on 21) A method for making a cancer vaccine comprising combining the composition of claim 21 with an adjuvant.